References
- Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol 2013;97:165–174.
- Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol 2013;20:100–106.
- Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006;57:225–244.
- Hofmann S, Gotz M, Schneider V, et al. Donor lymphocyte infusion induces polyspecific CD8 + T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol 2013;31:e44–e47.
- Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012;120:1282–1289.
- Olson BM, McNeel DG. Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines 2012;11:1315–1317.
- Schneider V, Egenrieder S, Gotz M, et al. Specific immune responses against epitopes derived from Aurora kinase A and B in acute myeloid leukemia. Leuk Lymphoma 2013;54:1500–1504.
- Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 2009;21: 524–530.